“Bristol-Myers Squibb said on Monday it would buy MyoKardia for about $13 billion to bolster its portfolio of heart disease treatments, as it seeks to reduce some of its dependence on cancer drugs. The deal follows Bristol-Myers’ $74 billion acquisition of Celgene last… Continue Reading…